BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld
Home
» Targacept, AstraZeneca Enter TC-1734 Deal For Up To $300M
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Targacept, AstraZeneca Enter TC-1734 Deal For Up To $300M
Dec. 29, 2005
By
Karen Carey
No Comments
Signing a deal worth up to $300 million for one product - and possibly more if others come into play - Targacept Inc. partnered worldwide rights to its Phase II cognitive disorder drug, TC-1734, with AstraZeneca plc. (BioWorld Today)
BioWorld